Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
TuHURA Biosciences ( (HURA) ) just unveiled an update.
TuHURA Biosciences has entered into a definitive merger agreement to acquire Kineta, Inc., a clinical-stage biotechnology company. This strategic acquisition includes Kineta’s novel KVA12123 antibody and is expected to enhance TuHURA’s late-stage pipeline with potential synergies in cancer immunotherapy. The merger is anticipated to close in the first quarter of 2025, pending certain approvals and conditions, which could significantly impact TuHURA’s operations and market position by expanding its capabilities in developing treatments for blood-related cancers.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies to overcome resistance to cancer immunotherapy. The company aims to address primary and acquired resistance to cancer treatments, offering solutions like the IFx-2.0 candidate and using Delta receptor technology to develop bi-specific ADCs and PDCs.
YTD Price Performance: -1.68%
Average Trading Volume: 253,051
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $246.9M
For an in-depth examination of HURA stock, go to TipRanks’ Stock Analysis page.
